A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden
Version of Record online: 8 DEC 2005
Acta Ophthalmologica Scandinavica
Volume 84, Issue 1, pages 74–83, February 2006
How to Cite
Lindblom, B., Nordmann, J.-P., Sellem, E., Chen, E., Gold, R., Polland, W., Williamson, W., Buchholz, P., Walt, J. G., Groleau, D., Curry, A. and Evans, S. J. (2006), A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmologica Scandinavica, 84: 74–83. doi: 10.1111/j.1600-0420.2005.00560.x
- Issue online: 8 DEC 2005
- Version of Record online: 8 DEC 2005
- Received on September 24th, 2004. Accepted on July 14th, 2005.
- ocular hypertension;
- intraocular pressure;
- treatment costs;
- health expenditures;
- health care costs
Purpose: To assess resource utilization and costs associated with glaucoma management in France and Sweden.
Methods: A total of 267 patient records (121 in France, 146 in Sweden) with diagnoses of primary open-angle glaucoma (POAG) and ocular hypertension (OH), treated medically, were reviewed for a 2-year period (beginning during 1997−99) for relevant clinical and resource utilization data. Economic data were applied to estimate treatment costs.
Results: The annual cost of treating glaucoma was estimated at SEK5305 (€531)/patient in Sweden and €390/patient in France. In both countries, medication costs comprised about half of the total costs. Surgical procedures and hospitalizations represented greater proportions of total cost in France (7.0% and 9.6%, respectively) than in Sweden (3.7% and 0.6%, respectively).
Conclusion: Medication costs represent a high proportion of total treatment costs. These findings highlight the relative importance of medical therapy and of assessing the cost-effectiveness of medications in glaucoma.